Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL938273 | 0.99 | MKNK1 (0.54) | MKNK1MKNK2KDRMETFGFR1 | |
| SCHEMBL12908971 | 0.92 | MKNK1 (0.53) | MKNK1MKNK2KDRMETFGFR1 | |
| Hydrochloric Acid SCHEMBL938634 | 0.91 | MKNK1 (0.52) | MKNK1MKNK2KDRMETFGFR1 | |
| SCHEMBL13473636 | 0.88 | MKNK1 (0.54) | MKNK1MKNK2KDRMETFGFR1 | |
| SCHEMBL12908964 | 0.78 | KDR (0.57) | MKNK1MKNK2KDRMETFGFR1 | |
| Hydrochloric Acid SCHEMBL939888 | 0.78 | KDR (0.56) | MKNK1MKNK2KDRMETFGFR1 | |
| SCHEMBL12944795 | 0.76 | MAPT (0.62) | MKNK1MKNK2KDRMETFGFR1 | |
| SCHEMBL12908963 | 0.76 | KDR (0.57) | MKNK1MKNK2KDRMETFGFR1 | |
| SCHEMBL938202 | 0.76 | EGFR (0.74) | MKNK1MKNK2KDRMETFGFR1 | |
| SCHEMBL938262 | 0.76 | FGFR1 (0.64) | MKNK1MKNK2KDRMETFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, CYP11B1, CYP11A1 | MKNK1 3496/4885MKNK2 3395/4885KDR 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.